By combining traditional prognostic factors, such as tumour size, grade, and hormone receptor status, with molecular and genomic insights, clinicians can develop personalised treatment strategies that are tailored to the unique biological characteristics of each patient’s cancer. The gene discussed is NR4A1; the disease is cancer.